For founders, investors and acquirers operating in European HealthTech, understanding this new shape of the market matters more than tracking any single quarterly funding figure. The headline numbers now tell contradictory stories depending on which slice you examine, European digital health funding in the first quarter of 2026 fell 44% year on year, yet first-half funding rose 60% over the same period. Both figures are accurate. Reconciling them is the key to understanding w

The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins, and predictable, capital-efficient exit pathways of the software industry. However, the combination of physical hardware development timelines, complex and

The Hungarian life sciences, medical technology, and biotechnology sectors represent a highly concentrated, export-driven industry defined by a strong academic foundation and a transition from traditional pharmaceutical manufacturing to advanced digital health, medical deep tech, and artificial intelligence. The sector comprises approximately 150 to 180 export-driven medical device manufacturing enterprises, alongside around 90 biotechnology companies and a broader network of

The European healthcare technology and clinical artificial intelligence sectors have transitioned into an era of disciplined industrialisation. The speculative fragmentation and "growth-at-all-costs" investment thesis that characterized the zero-interest-rate policy era have been replaced by a rigorous focus on unit economics, real-world clinical evidence, and deep workflow integration. As the market approaches the second half of 2026, venture capital deployment in clinical A